Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lemborexant in Healthy Chinese Subjects

NCT04555733 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT04555733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04555733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lemborexant in Healthy Chinese Subjects
Lead sponsor
Eisai Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
October 26, 2020
Completion date
January 13, 2021
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer